The efficacy of the Oxford/AstraZeneca vaccine in children is due to be tested in a new clinical trial beginning this month.
Researchers will use 300 volunteers to assess whether the jab – known as the the ChAdOx1 nCoV-19 vaccine – produces a strong immune response in children aged between six and 17.
The Oxford jab is one of three to have already been approved for use in adults in the UK, along with those from Pfizer/BioNTech and Moderna.
The Royal College of Paediatrics and Child Health has said it was rare for Covid-19 to cause death and severe illness to children.
“In children, the evidence is now clear that Covid-19 is associated with a considerably lower burden of morbidity and mortality compared to that seen in the elderly,” it said.